Research programme: HIV viral entry inhibitors - Sienna Biopharmaceuticals
Alternative Names: CT 319; CT 326; HIV viral entry inhibitors research programme - Sienna BiopharmaceuticalsLatest Information Update: 15 Dec 2016
At a glance
- Originator Creabilis Therapeutics; University of Turin
- Class
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 06 Dec 2016 Creabilis Therapeutics has been acquired by Sienna Biopharmaceuticals
- 01 Sep 2005 Preclinical trials in HIV infections prevention in Italy (unspecified route)